4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2025)
Historic Operating Leases for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $16.6 million.
- 4D Molecular Therapeutics' Operating Leases fell 1608.16% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 1608.16%. This contributed to the annual value of $19.0 million for FY2024, which is 6463.29% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Operating Leases stood at $16.6 million, which was down 1608.16% from $17.4 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Operating Leases registered a high of $19.7 million during Q3 2024, and its lowest value of $10.5 million during Q2 2024.
- For the 5-year period, 4D Molecular Therapeutics' Operating Leases averaged around $14.6 million, with its median value being $14.2 million (2022).
- As far as peak fluctuations go, 4D Molecular Therapeutics' Operating Leases crashed by 1650.04% in 2024, and later skyrocketed by 6592.73% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Operating Leases stood at $15.2 million in 2021, then fell by 11.49% to $13.5 million in 2022, then decreased by 14.46% to $11.5 million in 2023, then skyrocketed by 64.63% to $19.0 million in 2024, then dropped by 12.66% to $16.6 million in 2025.
- Its Operating Leases was $16.6 million in Q3 2025, compared to $17.4 million in Q2 2025 and $18.2 million in Q1 2025.